BR9201848A - Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos - Google Patents

Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos

Info

Publication number
BR9201848A
BR9201848A BR929201848A BR9201848A BR9201848A BR 9201848 A BR9201848 A BR 9201848A BR 929201848 A BR929201848 A BR 929201848A BR 9201848 A BR9201848 A BR 9201848A BR 9201848 A BR9201848 A BR 9201848A
Authority
BR
Brazil
Prior art keywords
virus
vaccines
vaccine
particuals
prophylaxis
Prior art date
Application number
BR929201848A
Other languages
English (en)
Inventor
John Sidney Oxford
Original Assignee
Retroscreen Ltd Companhia Brit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retroscreen Ltd Companhia Brit filed Critical Retroscreen Ltd Companhia Brit
Publication of BR9201848A publication Critical patent/BR9201848A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Telephone Function (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR929201848A 1991-05-17 1992-05-15 Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos BR9201848A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110808A GB9110808D0 (en) 1991-05-17 1991-05-17 Aids vaccine and method for its production

Publications (1)

Publication Number Publication Date
BR9201848A true BR9201848A (pt) 1993-01-05

Family

ID=10695252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR929201848A BR9201848A (pt) 1991-05-17 1992-05-15 Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos

Country Status (16)

Country Link
US (1) US5698432A (pt)
EP (1) EP0514199B1 (pt)
JP (1) JPH05328967A (pt)
KR (1) KR0149182B1 (pt)
AT (1) ATE172642T1 (pt)
AU (1) AU652447B2 (pt)
BR (1) BR9201848A (pt)
CA (1) CA2068817A1 (pt)
DE (1) DE69227400T2 (pt)
ES (1) ES2127203T3 (pt)
GB (1) GB9110808D0 (pt)
IE (1) IE921556A1 (pt)
IN (1) IN174080B (pt)
NZ (1) NZ242780A (pt)
SG (1) SG49763A1 (pt)
ZA (1) ZA923607B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131427T2 (de) * 1991-05-28 1999-11-25 Kabushiki Kaisha Toshiba, Kawasaki Arbeitsvorrichtung
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
DE19520216C2 (de) * 1995-06-01 1997-04-10 Frey Rainer H Vakzine zur Prophylaxe und Therapie von AIDS, und Verfahren zur Herstellung
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6352695B1 (en) 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
DE19916085A1 (de) * 1998-10-28 2000-05-04 Sonntag Hans Guenther Verfahren zur Herstellung eines antiviralen Mittels
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
TR200202104T2 (tr) * 1999-12-20 2002-12-23 Agricultural Research Council Mikroorganizmaların etkisiz hale getirilmesi yöntemi.
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US7033500B2 (en) * 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2003048366A1 (en) * 2001-12-07 2003-06-12 Postech Foundation Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
CA2531227A1 (en) 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
EP2192917B1 (en) * 2007-08-28 2014-01-29 Baxter International Inc. Method for producing viral vaccines
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
EA034543B1 (ru) 2012-06-01 2020-02-19 Бёрингер Ингельхайм Ветмедика Гмбх Иммуногенная композиция (вакцина) против вируса шмалленберга (sbv), способ ее получения и способ индукции иммунного ответа против sbv
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP5865942B2 (ja) 2014-04-16 2016-02-17 三菱電機株式会社 内燃機関のシリンダ吸入空気量推定装置および推定方法
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CA3083194A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN111629751B (zh) 2018-01-22 2025-02-21 美国政府(由卫生和人类服务部的部长所代表) 广泛保护性灭活流感病毒疫苗
US11643641B2 (en) * 2021-03-04 2023-05-09 Malireddy S. Reddy Prevention of viral transmission by naked genetic material

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
DE2321951C2 (de) * 1973-05-02 1975-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer Diphtherie-Vaccine
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia
GB1503388A (en) * 1975-07-01 1978-03-08 Inverni Della Beffa Spa Pharmaceutically active complexes and pharmaceutical compositions containing them
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4645666A (en) * 1982-06-08 1987-02-24 The Regents Of The University Of California Vaccine for bluetongue disease employing platinum compounds
US4530831A (en) * 1982-11-02 1985-07-23 Akzo N.V. Infectious Bursal Disease vaccine
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
EP0250128A3 (en) * 1986-06-18 1988-06-08 American Registry of Pathology Novel virus isolated from patients with aids
DE3707987A1 (de) * 1987-03-12 1988-09-22 Behringwerke Ag Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole
GB8906794D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Preparation of vaccines

Also Published As

Publication number Publication date
ATE172642T1 (de) 1998-11-15
IN174080B (pt) 1994-09-10
JPH05328967A (ja) 1993-12-14
ES2127203T3 (es) 1999-04-16
EP0514199A2 (en) 1992-11-19
CA2068817A1 (en) 1992-11-18
GB9110808D0 (en) 1991-07-10
EP0514199B1 (en) 1998-10-28
NZ242780A (en) 1994-07-26
AU652447B2 (en) 1994-08-25
US5698432A (en) 1997-12-16
EP0514199A3 (en) 1993-11-10
KR0149182B1 (ko) 1998-10-15
KR920021162A (ko) 1992-12-18
IE921556A1 (en) 1992-11-18
DE69227400D1 (de) 1998-12-03
SG49763A1 (en) 1998-06-15
DE69227400T2 (de) 1999-07-01
ZA923607B (en) 1993-02-24
AU1634092A (en) 1992-12-17

Similar Documents

Publication Publication Date Title
BR9201848A (pt) Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos
PT97754A (pt) Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus
BR9712138A (pt) Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
BR9712592A (pt) Processo para gerar um clone infeccioso, ácido nucléico recombinante, molécula do mesmo, vìrus de rna modificado, célula infectada com o mesmo, vacina, proteìna e/ou antìgeno, e, ensaio diagnóstico
ATE217144T1 (de) Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren
ATE544466T1 (de) Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
ES2107609T3 (es) Polipeptidos sinteticos como inhibidores de vih-1.
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
ATE364624T1 (de) Multisystemisches kümmerwuchssyndrom durch viren in schweine
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
BR9106879A (pt) Virus mutuante nao retroviral,uso do mesmo,vacina e processo de manufaturar umvirus mutante
BR9106747A (pt) Oligonucleotideo ou analogo de oligonucleotideo e processo para tratamento de um animal suspeito de estar infectado por virus da influenza
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
DE3684255D1 (de) Thymidinkinase-deletionsmutanten von bovinem herpesvirus-1, diese enthaltende impfstoffe gegen bovine rhinotracheitis und verfahren zu deren herstellung und verwendung.
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
ES2113348T3 (es) Composiciones de vacunas estabilizadas.
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
EP0507179A3 (en) Equine herpes viruses (ehv) containing foreign dna, process for their preparation and their use as vaccines
BR9707400A (pt) Vacinas contra produto do gene 63 de vìrus varicella zoster.
WO1999057284A3 (en) Attenuated influenza viruses
YU57994A (sh) Postupak za inaktiviranje virusa u prisustvu polialkilenglikola i farmaceutski preparat dobijen tim postupkom
BR0108442A (pt) Mutantes-ehv gm-negativos

Legal Events

Date Code Title Description
EE Request for examination
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal
FC Decision: refusal